

Eapm Working Group For Oncology Clin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5645585/publications.pdf>

Version: 2024-02-01

61
papers

5,025
citations

236612

25
h-index

168136

53
g-index

62
all docs

62
docs citations

62
times ranked

8571
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment landscape of triple-negative breast cancer “ expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
2	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	2.1	3
3	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	2.3	17
4	Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 633.	1.8	2
5	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	2.3	67
6	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	1.7	10
7	Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioltaLEE trial. <i>Cancer Research</i> , 2022, 82, GS3-07-GS3-07.	0.4	5
8	Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2167-2179.	3.2	8
9	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
10	Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers. <i>Frontiers in Medicine</i> , 2022, 9, 863468.	1.2	1
11	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
12	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	0.8	9
13	Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioltaEE trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1012-1012.	0.8	3
14	Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?. <i>Breast</i> , 2021, 55, 45-54.	0.9	10
15	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5096-5108.	3.2	12
16	Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. <i>Oncologist</i> , 2020, 25, e1013-e1020.	1.9	28
17	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. <i>Cancer Research</i> , 2020, 80, GS3-04-GS3-04.	0.4	90
18	Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 555-555.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Is trastuzumab as a single agent obsolete in early breast cancer? No. <i>Breast</i> , 2019, 43, 142-145.	0.9	1
20	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 39-47.	1.1	28
21	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 196.	1.8	0
22	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13012-e13012.	0.8	0
23	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 16.	2.2	83
24	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.4	76
25	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3317-3324.	0.4	117
26	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1707.	3.4	129
27	Gemcitabine-induced Thrombocytosis as a Potential Predictive Factor in Non-small Cell Lung Cancer: Analysis of 318 Patients. <i>Tumori</i> , 2017, 103, 143-147.	0.6	5
28	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. <i>Cancer Science</i> , 2016, 107, 1730-1735.	1.7	125
29	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
30	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 223-234.	1.1	3
31	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 2105-2110.	3.2	124
32	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345.	3.2	58
33	Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-517.	0.8	2
34	Association between DNA level aberrations and immune cell infiltration in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3078-3078.	0.8	0
35	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 1-3.	0.9	0
36	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. <i>Public Health Genomics</i> , 2015, 18, 349-358.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015, 5, 972-987.	7.7	97
38	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0123194.	1.1	11
39	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11021-11021.	0.8	0
40	Low tumor-infiltrating lymphocytes (TILs) to predict and refine risk in patients not achieving a pathological complete response (pCR) in HER2-positive breast cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11612-e11612.	0.8	0
41	OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1196-1207.	2.1	17
42	<i>TP53</i> mutationâ€correlated genes predict the risk of tumor relapse and identify <i>MPS1</i> as a potential therapeutic kinase in <i>TP53</i> â€mutated breast cancers. <i>Molecular Oncology</i> , 2014, 8, 508-519.	2.1	59
43	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	5.1	244
44	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. <i>Clinical Cancer Research</i> , 2014, 20, 511-521.	3.2	191
45	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. <i>PLoS ONE</i> , 2014, 9, e86511.	1.1	10
46	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 530-530.	0.8	0
47	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. <i>Oncologist</i> , 2013, 18, 1063-1073.	1.9	75
48	Breast Cancer Genomics: Challenges in Interpretation and Application. <i>Oncologist</i> , 2013, 18, e11-2.	1.9	1
49	HER2-Directed T-Cell Receptorâ€Mimicking Antibody: A â€Me Tooâ€or an Example of Novel Antitumor Aggressive Mimicry?. <i>Journal of the National Cancer Institute</i> , 2013, 105, 161-163.	3.0	1
50	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	2.2	44
51	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1014-1014.	0.8	2
52	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	1.7	19
53	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 785-795.	1.1	68
54	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 155-164.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy. Journal of the National Cancer Institute Monographs, 2011, 2011, 91-94.	0.9	2
56	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
57	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research, 2011, 17, 2591-2601.	3.2	52
58	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. Cancer Cell, 2010, 18, 423-435.	7.7	129
59	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptorâ€‘positive, HER2â€‘normal, grade II, lymph nodeâ€‘negative breast cancers. Cancer, 2010, 116, 5161-5167.	2.0	87
60	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.4	58
61	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptorâ€‘Positive and â€‘Negative Cancers. Journal of Clinical Oncology, 2010, 28, 4316-4323.	0.8	193